Spectrum Pharma

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Henderson, NV.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spectrum Pharmaceuticals is a biopharmaceutical company that focuses on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus on oncology. It has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development.

Spectrum Pharma (SPPI) misses bottom-line estimates for the fourth quarter and records no revenues. Shares down.

Spectrum Pharma (SPPI) Incurs Wider-Than-Expected Q4 Loss

Spectrum Pharmaceuticals, Inc.'s (SPPI) CEO Joseph Turgeon on Q4 2019 Results - Earnings Call Transcript

Progress of its pipeline candidates is likely to have increased Spectrum Pharmaceuticals' (SPPI) operating expenses in the fourth quarter.

What Awaits Spectrum Pharmaceuticals (SPPI) in Q4 Earnings?

Spectrum Pharmaceuticals (SPPI) closed the most recent trading day at $3.24, moving -1.52% from the previous trading session.

Spectrum Pharmaceuticals (SPPI) Stock Sinks As Market Gains: What You Should Know

Spectrum Pharmaceuticals: Stock Price Drop Vs Disappointing Clinical Data Provides Good Upside

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), which plummeted 60% to $3.50 Thursday in reaction to a negative clinical readout, were rebounding Friday.

Spectrum Pharma Analyst Says Sell-Off May Have Been Overdone

Spectrum Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Spectrum Pharmaceuticals is Oversold: Can It Recover?

Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) shares were halved on Thursday after the firm provided an update on its midstage cancer study.

Why This Cancer Study Is Crushing Spectrum Pharma

Spectrum Pharmaceuticals Inc. shares  fell 17% in premarket trade Thursday after the company said a mid-stage trial of a treatment for non-small cell lung cancer, or NSCLC, missed its main goal.

Spectrum Pharma shares slide 17% premarket after trial of lung cancer treatment misses main goal

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

Why Is Spectrum Pharma (SPPI) Up 23.9% Since Last Earnings Report?

As of late, it has definitely been a great time to be an investor in Spectrum Pharmaceuticals.

Will Spectrum Pharmaceuticals Continue to Surge Higher?

Investors need to pay close attention to Spectrum Pharmaceuticals (SPPI) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Spectrum Pharmaceuticals (SPPI) Stock

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joseph Turgeon on Q3 2019 Results - Earnings Call Transcript

Spectrum Pharma (SPPI) posts a narrower-than-expected loss for the third quarter of 2019.

Spectrum Pharma's (SPPI) Q3 Loss Narrows, Focus on Rolontis

Investors need to pay close attention to Spectrum Pharma (SPPI) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Spectrum Pharma (SPPI) Stock?

Spectrum Pharma (SPPI) Down 0.7% Since Last Earnings Report: Can It Rebound?

Early ORR results in NSCLC with exon 20 mutation for lead candidate poziotinib pushed the stock over $20.00/share in 2018.

Behind The Idea: Spectrum Pharmaceuticals - Great Asset, Great Liquidity, Low Price

Behind The Idea: Spectrum Pharma - Great Asset

Spectrum Pharma (SPPI) beats bottom-line estimates in the second quarter.

Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q2 2019 Results - Earnings Call Transcript

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 28.13% and -349.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Spectrum Pharmaceuticals (SPPI) Reports Q2 Loss, Misses Revenue Estimates

Spectrum Pharma (SPPI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Spectrum Pharmaceuticals (SPPI) to Report a Decline in Earnings: What to Look Out for

Alexion Pharma

Novelion Therapeutics

Novartis

Spark Therapeutics

The upward trajectory of prescription drug prices in the U.S. has drawn the ire of lawmakers.

The 5 Most Expensive Drugs In US: What You Should Know

In the late 2000s, Spectrum captured the heightened demand of leucovorin shortage with Fusilev. This benefits patients while conferring shareholders one of the most prosperous periods in the company's history.

News for Spectrum Pharma Stock (SPPI)